Related Experiment Video
Updated: Mar 6, 2026
Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
A pharmacological approach in newly established retinal vein occlusion model
Shinichiro Fuma1, Anri Nishinaka1, Yuki Inoue1
1Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Abstract:
The mechanism underlying the effects of anti-vascular endothelial growth factor (VEGF) antibody in retinal vein occlusion (RVO) treatment is poorly understood, partly due to the lack of RVO animal models that mimic clinical pathology. The aims of this study were to establish a suitable RVO model, clarify the pathogenic mechanisms, and evaluate the effects of anti-VEGF antibody in the model. Mouse retinal veins were occluded by laser photocoagulation after rose bengal injection. Reduction of the b/a wave amplitude ratio, retinal nonperfusion, cystoid edema, and hard exudates were observed after occlusion, and expression of RVO-related genes was altered. Administration of anti-VEGF antibody immediately, or 7 days, after occlusion resulted in reduction and increase of the nonperfused area, respectively. We conclude that the present model will be useful for clarification of the pathogenic mechanisms, and that the timing of anti-VEGF antibody administration is important for the successful amelioration of retinal nonperfusion.
Insights
Developing an effective retinal vein occlusion (RVO) animal model is crucial. This study shows anti-vascular endothelial growth factor (VEGF) antibody timing impacts RVO treatment success.
Area of Science:
- Ophthalmology
- Vascular Biology
- Animal Models
Background:
- The therapeutic mechanisms of anti-vascular endothelial growth factor (VEGF) antibodies in retinal vein occlusion (RVO) are not fully understood.
- A lack of appropriate animal models hinders research into RVO pathogenesis and treatment.
Purpose of the Study:
- To establish a novel laser-induced mouse model of RVO.
- To elucidate the pathogenic mechanisms involved in RVO.
- To evaluate the efficacy of anti-VEGF antibody treatment in this RVO model.
Main Methods:
- Retinal vein occlusion was induced in mice using laser photocoagulation and rose bengal injection.
- Ophthalmic assessments included electroretinography, funduscopy, and optical coherence tomography.
- Gene expression analysis was performed to identify RVO-related molecular changes.
Main Results:
- The established RVO model exhibited characteristic features such as reduced b/a wave amplitude ratio, retinal nonperfusion, cystoid edema, and hard exudates.
- Gene expression profiles were significantly altered following venous occlusion.
- Immediate administration of anti-VEGF antibody reduced the nonperfused area, whereas delayed administration (7 days post-occlusion) increased it.
Conclusions:
- The developed laser-induced mouse model effectively mimics key aspects of human RVO pathology.
- The timing of anti-VEGF antibody administration is a critical factor influencing treatment outcomes in RVO.
- This model provides a valuable platform for further investigation into RVO pathogenesis and therapeutic strategies.
